Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
Authors:
- Peter A. MerkelPMPeter A. Merkel
- Karen HerlynKHKaren Herlyn
- Alfred D. MahrAMAlfred D. Mahr
- Tuhina NeogiTNTuhina Neogi
- Philip SeoPSPhilip Seo
- Michael WalshMWMichael Walsh
- Maarten BoersMBMaarten Boers
- Raashid LuqmaniRLRaashid Luqmani
- 8 October 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (10) , 2362-2368
Abstract
The past decade has seen a substantial increase in the number and quality of clinical trials of new therapies for vasculitis, including randomized, controlled, multicenter trials that have successfully incorporated measures of disease activity and toxicity. However, because current treatment regimens for severe disease effectively induce initial remission and reduce mortality, future trials will focus on any of several goals including: (a) treatment of mild—moderate disease; (b) prevention of chronic damage; (c) reduction in treatment toxicity; or (d) more subtle differences in remission induction or maintenance. Thus, new trials will require outcome measure instruments that are more precise and are better able to detect effective treatments for different disease states and measure chronic manifestations of disease. The OMERACT Vasculitis Working Group comprises international clinical investigators with expertise in vasculitis who, since 2002, have worked collaboratively to advance the refinement of outcome measures in vasculitis, create new measures to address domains of illness not covered by current research approaches, and harmonize outcome assessment in vasculitis. The focus of the OMERACT group to date has been on outcome measures in small-vessel vasculitis with an overall goal of creating a core set of outcome measures for vasculitis, each of which fulfills the OMERACT filter of truth, discrimination, feasibility, and identifying additional domains requiring further research. This process has been informed by several ongoing projects providing data on outcomes of disease activity, disease-related damage, multidimensional health-related quality of life, and patient-reported ratings of the burden of vasculitis.Keywords
This publication has 33 references indexed in Scilit:
- Assessment of damage in vasculitis: expert ratings of damageRheumatology, 2009
- Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitisAnnals of the Rheumatic Diseases, 2009
- Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegener's GranulomatosisArthritis Care & Research, 2008
- Wegener's granulomatosis: managing more than inflammationCurrent Opinion in Rheumatology, 2008
- Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal VasculitisJournal of the American Society of Nephrology, 2007
- Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Arthritis & Rheumatism, 2005
- Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self‐reported health‐related quality of life early in the disease courseArthritis Care & Research, 2004
- A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritisArthritis & Rheumatism, 2002
- Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnairesArchives of internal medicine (1960), 1990
- Analysis of quality of life data from a randomized, placebo-controlled heart-failure trialJournal of Clinical Epidemiology, 1989